Computer-supported visualisation of distributed production area information von Stowasser, S.

Volltext

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases von Flaherty, Kevin R, Wells, Athol U, Cottin, Vincent, Devaraj, Anand, Walsh, Simon L.F, Inoue, Yoshikazu, Richeldi, Luca, Kolb, Martin, Tetzlaff, Kay, Stowasser, Susanne, Coeck, Carl, Clerisme-Beaty, Emmanuelle, Rosenstock, Bernd, Quaresma, Manuel, Haeufel, Thomas, Goeldner, Rainer-Georg, Schlenker-Herceg, Rozsa, Brown, Kevin K

Volltext

Trial of a phosphodiesterase 4 inhibitor for idiopathic pulmonary fibrosis. reply von Richeldi, L, Stowasser, S, Maher, TM

Volltext

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib von Bonella, Francesco, Stowasser, Susanne, Wollin, Lutz

Volltext

Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis von Richeldi, L, Azuma, A, Cottin, V, Hesslinger, C, Stowasser, S, Valenzuela, C, Wijsenbeek, MS, Zoz, DF, Voss, F, Maher, TM, 1305-0013 Trial Investigators

Volltext

Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort von Williams, Tracy A, PhD, Lenders, Jacques W M, Prof, Mulatero, Paolo, MD, Burrello, Jacopo, MD, Rottenkolber, Marietta, MS, Adolf, Christian, MD, Satoh, Fumitoshi, Prof, Amar, Laurence, MD, Quinkler, Marcus, MD, Deinum, Jaap, MD, Beuschlein, Felix, Prof, Kitamoto, Kanako K, MD, Pham, Uyen, MD, Morimoto, Ryo, MD, Umakoshi, Hironobu, MD, Prejbisz, Aleksander, MD, Kocjan, Tomaz, MD, Naruse, Mitsuhide, Prof, Stowasser, Michael, Prof, Nishikawa, Tetsuo, MD, Young, William F, Prof, Gomez-Sanchez, Celso E, Prof, Funder, John W, Prof, Reincke, Martin, Prof

Volltext

Meta-analysis of effect of nintedanib on reducing FVC decline across interstitial lung diseases von Bonella, F, Cottin, V, Valenzuela, C, Wijsenbeek, M, Voss, F, Rohr, KB, Stowasser, S, Maher, TM

Volltext

S108 Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials von Kolb, M, Kimura, T, Stowasser, S, Hallmann, C, Richeldi, L

Volltext

M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf von Richeldi, L, Kolb, M, Azuma, A, Stansen, W, Quaresma, M, Stowasser, S, Crestani, B

Volltext

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial von Noth, I, Cottin, V, Chaudhuri, N, Corte, TJ, Johannson, KA, Wijsenbeek, M, Jouneau, S, Michael, A, Quaresma, M, Rohr, KB, Russell, A-M, Stowasser, S, Maher, TM, INMARK trial investigators

Volltext

C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Dose Reductions And/or Interruptions On The Efficacy Of Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Subgroup A... von Maher, T M, Inoue, Y, Case, A H, Sakamoto, W, Stowasser, S, Wuyts, W A

Volltext

C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Patient Demographic And Functional Characteristics On Long-Term Efficacy Of Nintedanib In Patients With Idiopathic Pulmonary Fibros... von Kreuter, M, Song, J, Huggins, J T, Quaresma, M, Stansen, W, Stowasser, S, Crestani, B

Volltext

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases von Wollin, L, Distler, JHW, Redente, EF, Riches, DWH, Stowasser, S, Schlenker-Herceg, R, Maher, TM, Kolb, M

Volltext

M30 Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (ipf): subgroup analysis of the inpulsis trials von Maher, TM, Inoue, Y, Case, AH, Sakamoto, W, Stowasser, S, Wuyts, WA

Volltext

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone von Richeldi, L, Fletcher, S, Adamali, H, Chaudhuri, N, Wiebe, S, Wind, S, Hohl, K, Baker, A, Schlenker-Herceg, R, Stowasser, S, Maher, TM

Volltext

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials von Kreuter, M, Wuyts, WA, Wijsenbeek, M, Bajwah, S, Maher, TM, Stowasser, S, Male, N, Stansen, W, Schoof, N, Orsatti, L, Swigris, J

Volltext

A103 IPF: MORE ABOUT THERAPY AND OUTCOMES: Effect Of Baseline Gap Index Stage On Decline In Lung Function With Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf) von Ryerson, C J, Kolb, M, Richeldi, L, Lee, J, Kimura, T, Stowasser, S, Poletti, V

Volltext

A103 IPF: MORE ABOUT THERAPY AND OUTCOMES: Effect Of Nintedanib On Disease Progression In The Inpulsis® Trials In Patients With Idiopathic Pulmonary Fibrosis (ipf) von Raghu, G, Inoue, Y, Behr, J, Cottin, V, Stowasser, S, Stansen, W, Maher, T M

Volltext

Nintedanib for systemic sclerosis-associated interstitial lung disease von Distler, O, Highland, KB, Gahlemann, M, Azuma, A, Fischer, A, Mayes, MD, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, TM, SENSCIS Trial Investigators

Volltext

S110 Efficacy and safety of nintedanib in patients with IPF beyond week 52: Data from the Phase II TOMORROW trial von Richeldi, L, Costabel, U, Selman, M, Xu, Z, Kimura, T, Stowasser, S, Hallmann, C

Volltext